CVR number 31745640
Industry 86.9020 Other human health activities

R FYS ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  10.8% 16.0% 7.3% 25.6% 25.3%  
Credit score (0-100)  24 11 32 2 2  
Credit rating  BB BB BBB B B  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Net sales  0 0 0 0 0  
Gross profit  377 132 444 32.2 68.4  
EBITDA  -495 5.0 362 -275 -166  
EBIT  -797 -316 211 -343 -217  
Pre-tax profit (PTP)  -845.8 -366.3 204.8 -205.9 -393.9  
Net earnings  -825.9 -296.2 166.9 -205.9 -393.9  
Pre-tax profit without non-rec. items  -846 -366 205 -206 -394  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Tangible assets total  30.8 13.5 1.4 0.0 0.0  
Shareholders equity total  -459 -756 -589 -795 -1,188  
Interest-bearing liabilities  989 908 0.0 0.0 639  
Balance sheet total (assets)  857 474 403 192 123  
Net Debt  989 901 -68.0 -20.4 633  
 
See the entire balance sheet

Volume 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  377 132 444 32.2 68.4  
Gross profit growth  -52.6% -64.9% 234.8% -92.7% 112.3%  
Employees  3 2 1 1 1  
Employee growth %  13.1% -35.7% -50.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  857 474 403 192 123  
Balance sheet change%  -41.0% -44.6% -15.0% -52.3% -36.2%  
Added value  -494.6 5.0 361.9 -192.6 -166.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -478 -490 -301 -136 -103  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 -1.0 -2.0  

Profitability 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -211.4% -238.2% 47.7% -1,065.1% -317.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -57.3% -24.3% 22.7% -18.2% -18.7%  
ROI %  -71.3% -32.4% 54.2% -1,499.3% -64.7%  
ROE %  -135.0% -44.5% 38.0% -69.2% -250.1%  

Solidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Equity ratio %  -34.9% -61.4% -59.4% -80.5% -90.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -199.9% 17,843.7% -18.8% 7.4% -381.3%  
Gearing %  -215.2% -120.2% 0.0% 0.0% -53.7%  
Net interest  0 0 0 0 0  
Financing costs %  5.7% 6.0% 10.5% 0.0% 56.2%  

Liquidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Quick Ratio  0.2 0.1 0.2 0.0 0.0  
Current Ratio  0.2 0.1 0.2 0.0 0.0  
Cash and cash equivalent  0.0 7.5 68.0 20.4 5.6  

Capital use efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1,001.1 -1,116.1 -798.7 -936.6 -1,278.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Net sales / employee  0 0 0 0 0  
Added value / employee  -159 3 362 -193 -166  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -159 3 362 -275 -166  
EBIT / employee  -256 -158 211 -343 -217  
Net earnings / employee  -266 -148 167 -206 -394